GE HealthCare, Mayo Clinic launch MI-BET study to personalize radioligand therapy in advanced prostate cancer

GE HealthCare and Mayo Clinic have launched the MI-BET study to personalize radioligand therapy for advanced prostate cancer. The research focuses on adaptive treatment strategies, such as pausing therapy based on individual response rather than fixed cycles. Utilizing StarGuide SPECT/CT and MIM LesionID Pro, the program aims to develop predictive markers for earlier decision-making. The study is based at Mayo Clinic’s Rochester campus.

GE HealthCare launched MI-BET, a Mayo Clinic research collaboration to test imaging- and biomarker-guided personalization of radioligand therapy in advanced prostate cancer. * Study targets adaptive treatment, including pausing therapy based on individual disease response instead of fixed treatment cycles. * Program uses StarGuide SPECT/CT with MIM LesionID Pro to track tumor response, aiming to develop predictive markers for earlier treatment decisions. * Work will be based at Mayo Clinic’s Rochester campus; Mayo will be the first US site to investigate StarGuide GX, which is not FDA-cleared. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GE HealthCare Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260708929448) on July 08, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

GE HealthCare launched MI-BET, a Mayo Clinic research collaboration to test imaging- and biomarker-guided personalization of radioligand therapy in advanced prostate cancer. * Study targets adaptive treatment, including pausing therapy based on individual disease response instead of fixed treatment cycles. * Program uses StarGuide SPECT/CT with MIM LesionID Pro to track tumor response, aiming to develop predictive markers for earlier treatment decisions. * Work will be based at Mayo Clinic’s Rochester campus; Mayo will be the first US site to investigate StarGuide GX, which is not FDA-cleared. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GE HealthCare Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260708929448) on July 08, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)